Tami L. Wahl
Government Affairs, Policy & Regulatory Advisor, Legislative Counsel | Establishing oversight without sacrificing innovation.
United States
[/fusion_text][/fusion_builder_column][fusion_builder_column type=”3_4″ type=”3_4″ layout=”3_4″ align_self=”auto” content_layout=”column” align_content=”flex-start” valign_content=”flex-start” content_wrap=”wrap” center_content=”no” column_tag=”div” target=”_self” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” sticky_display=”normal,sticky” order_medium=”0″ order_small=”0″ hover_type=”none” border_style=”solid” box_shadow=”no” box_shadow_blur=”0″ box_shadow_spread=”0″ background_type=”single” gradient_start_position=”0″ gradient_end_position=”100″ gradient_type=”linear” radial_direction=”center center” linear_angle=”180″ lazy_load=”avada” background_position=”left top” background_repeat=”no-repeat” background_blend_mode=”none” sticky=”off” sticky_devices=”small-visibility,medium-visibility,large-visibility” absolute=”off” filter_type=”regular” filter_hover_element=”self” filter_hue=”0″ filter_saturation=”100″ filter_brightness=”100″ filter_contrast=”100″ filter_invert=”0″ filter_sepia=”0″ filter_opacity=”100″ filter_blur=”0″ filter_hue_hover=”0″ filter_saturation_hover=”100″ filter_brightness_hover=”100″ filter_contrast_hover=”100″ filter_invert_hover=”0″ filter_sepia_hover=”0″ filter_opacity_hover=”100″ filter_blur_hover=”0″ transform_type=”regular” transform_hover_element=”self” transform_scale_x=”1″ transform_scale_y=”1″ transform_translate_x=”0″ transform_translate_y=”0″ transform_rotate=”0″ transform_skew_x=”0″ transform_skew_y=”0″ transform_scale_x_hover=”1″ transform_scale_y_hover=”1″ transform_translate_x_hover=”0″ transform_translate_y_hover=”0″ transform_rotate_hover=”0″ transform_skew_x_hover=”0″ transform_skew_y_hover=”0″ transition_duration=”300″ transition_easing=”ease” scroll_motion_devices=”small-visibility,medium-visibility,large-visibility” animation_direction=”left” animation_speed=”0.3″ animation_delay=”0″ last=”true” border_position=”all” first=”false” min_height=”” link=””][fusion_text fusion_font_variant_text_font=”400″ fusion_font_family_text_font=”Raleway Regular” content_alignment=”left”][/fusion_text][fusion_accordion border_size=”1″ title_tag=”h4″ hide_on_mobile=”small-visibility,medium-visibility,large-visibility”][fusion_toggle title=”What significant changes have you observed in women’s health recently?” open=”no”]
One notable change has been the confluence of interest in women’s health from a broad cross section of stakeholders to include women, innovators, investors, software engineers, practitioners, and politicians. To further bolster, modern health technologies and the demand for individualized health care have also played a role in broadening the pool of interested parties. Once critical mass is established, the possibilities are endless.
[/fusion_toggle][fusion_toggle title=”Based on your experience, what are the major challenges in the next three years?” open=”no”]The level of interest in and number of innovators entering the women’s health space is off the chart; however, a major challenge that may ultimately curtail the interest (and investment dollars) is the lack of curiosity in pursuing new pathways to market. Forcing modern applications and ‘devices’ into a dated system may ultimately throttle innovation and slow the adoption of newer technologies. Industry is absolutely positioned to deliver fresh, viable pathways to market. Industry could also stumble and stay in the square peg, round hole dynamic.
[/fusion_toggle][fusion_toggle title=”What could be a catalyst to address these challenges?” open=”no”]One key catalyst for the women’s health tech sector to continue to thrive is to collectively establish that individuals fundamentally own their health data. This shift would be a landmark measure in approaching health and product development (e.g., licensing opportunities, access to real time data on product performance).
A catalyst for product developers to stay engaged and in turn, continue to bring investment dollars to the cause, is to push back that every at-home product needs to be cleared as a medical device. This translates to shorter timelines and fewer dollars to enter the market. And if this savings is reflected in the cost of the product to the end-user, there is the potential for greater adoption (use) of the product.
Related Posts
